Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Lymphoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Anus Neoplasms 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

pembrolizumab 30Nivolumab 30cabozantinib 20Ipilimumab 15Magnetic Resonance Spectroscopy 14belzutifan 13lenvatinib 11Axitinib 9Specimen Handling 8Sunitinib 7durvalumab 5CTLA-4 Antigen 5tislelizumab 4atezolizumab 4Radiosurgery 4Interleukin-2 4Everolimus 4Biopsy 4Bevacizumab 4pazopanib 3avelumab 3aldesleukin 3Immunoglobulin G 3Disulfides 3palbociclib 2fludarabine 2entinostat 2adavosertib 2Surveys and Questionnaires 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Renal Cell × entinostat × Clear all
NCT01038778 2026-04-13

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
47 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

NCT03501381 2023-09-01

High Dose IL 2 and Entinostat in RCC

Hoosier Cancer Research Network

Phase 2 Active not recruiting
46 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡